Remimazolam Besylate Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 20 mg, 50 mg
Reference Brands: Byfavo (USA/EU)
Category:
Anaesthetics
Remimazolam besylate is available in Injection
and strengths such as 20 mg, 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Remimazolam besylate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Remimazolam besylate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Remimazolam besylate is a short-acting benzodiazepine derivative with sedative-hypnotic properties, structurally related to midazolam. It is designed for intravenous use and is primarily indicated for procedural sedation and anesthesia in adults. Remimazolam acts by selectively targeting the gamma-aminobutyric acid (GABA)-A receptor complex on neuronal cell membranes. Upon binding to a specific allosteric site on the GABA-A chloride ionophore receptor, it enhances the affinity of GABA for the receptor.
This interaction increases the frequency of chloride channel opening, leading to an influx of chloride ions into the neuron. The resulting increase in chloride ion conductance causes neuronal hyperpolarization, inhibition of action potential firing, and a reduction in neuronal excitability, producing its sedative and hypnotic effects. Remimazolam besylate is characterized by a rapid onset and short duration of action due to its metabolism by tissue esterases, independent of hepatic cytochrome enzymes.
Its pharmacokinetic profile allows for predictable sedation, rapid recovery, and improved control during short medical procedures. Additionally, its effects can be reversed with flumazenil, providing an added safety advantage in clinical settings.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing